# Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)

> **NCT01293006** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 25 (actual)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** suvorexant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01293006
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-25
- **Primary completion:** 2012-01-20
- **Final completion:** 2012-02-22
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01293006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01293006, "Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01293006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*